Detalhe da pesquisa
1.
Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial.
Lancet Oncol
; 12(12): 1125-33, 2011 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-22019520
2.
Metastatic Breast Tumour Regression Following Treatment by a Gene-Modified Vaccinia Virus Expressing MUC1 and IL-2.
J Biomed Biotechnol
; 2003(3): 194-201, 2003.
Artigo
em Inglês
| MEDLINE | ID: mdl-12975534
3.
A phase II study of Tg4010 (Mva-Muc1-Il2) in association with chemotherapy in patients with stage III/IV Non-small cell lung cancer.
J Thorac Oncol
; 3(7): 735-44, 2008 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-18594319
4.
Gene-based vaccines and immunotherapeutics.
Proc Natl Acad Sci U S A
; 101 Suppl 2: 14567-71, 2004 Oct 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-15333750
5.
Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen-specific immunotherapy in patients with MUC1-positive advanced cancer.
J Gene Med
; 5(8): 690-9, 2003 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-12898638